[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.255.49. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Contribution
August 2008

Thrombolysis in Patients With Marked Clinical Fluctuations in Neurologic Status Due to Cerebral Ischemia

Author Affiliations

Author Affiliations: London Health Science Centre and Department of Neurological Sciences, University of Western Ontario, London, Ontario, Canada.

Arch Neurol. 2008;65(8):1041-1043. doi:10.1001/archneur.65.8.1041
Abstract

Background  It is unclear whether thrombolysis benefits patients with fluctuating neurologic symptoms.

Objective  To evaluate the clinical course of patients with acute stroke who presented with marked fluctuations in neurologic status and received thrombolytic therapy.

Design  Prospective analysis.

Setting  London Health Science Centre University Hospital, London.

Patients  We prospectively identified patients who were treated with intravenous or intra-arterial recombinant tissue plasminogen activator between January 1, 2004, and January 1, 2006. For this analysis, we chose patients who had marked fluctuation in neurologic status at presentation and who received thrombolytic therapy.

Main Outcome Measure  Fluctuation of neurologic deficits, defined as a 4-point or greater increase or decrease in the National Institutes of Health Stroke Scale (NIHSS) score.

Results  Among 127 patients, 13 (10.2%) had clinical fluctuations. Patients with fluctuations presented with a lower NIHSS score (median, 7; interquartile range, 10-17) compared with patients without fluctuations (median, 12; interquartile range, 10-17) (P < .001). Fluctuation of symptoms or signs ceased after thrombolysis. At 24 hours after stroke, the median NIHSS score was 2 (range, 1-12). All patients had favorable neurologic and functional outcomes at 3 months after thrombolysis (modified Rankin scale score, 0-2).

Conclusion  Thrombolysis may benefit patients with fluctuating symptoms or signs due to cerebral ischemia.

×